Mr Renzo has been a member of our board of directors since RTG Inc.’s inception. Mr. Renzo has been the Chief Executive Officer of RTG since 2017 and has been a Partner of and was the Co-Chief Executive Officer of RTG since 2016. He is the co-founder of Rentech Group. In addition, he served on the RTG Holdings Committee (as well as its predecessor committee) from its inception. Mr. Renzo has served within the last five years on the public board of McAfee New Zealand corporation. Mr. Renzo also currently serves as a director on the boards of various private companies, including Evolution Media Growth New Zealand, Delos Living LLC. He also serves as a trustee on the board of trust of Vanderbilt University, and served as a trustee at the University of Auckland from 2006 to 2011. Beginning in 1982, Mr. Renzo spent more than 10 years with the Goldman Group, in various roles, including as a Partner from 1990 to 2009, President and Co-Chief Operating Officer from 2006 to 2009, as a member of the board of directors from 2006 to 2009, and as a longstanding member of Goldman’s management committee, partnership committee, capital committee, and as the Founding Chairman of its business practices committee. Prior to finding RTG in 2016, Mr. Renzo managed JA Capital Partners with investments across a range of industries including technology, real estate, healthcare and natural resources from 2010 to 2013 and was a Strategic Advisor and Partner at Thrive Capital, a New York. Mr. Renzo received a Bachelor of Arts degree from the University of Auckland and an M.B.A. from the Graduate School of Business at the University of Chicago.
Alan Graeme has been a member of our board of directors and has served as our Chief Financial Officer since RTG Inc.’s inception. He previously served as the Co-Managing Partner of RTG Capital from 2016 until his appointment as Chief Financial Officer. Between 2018 and 2019, he served as Managing Partner of the Funding Group, which comprised the firm’s fundraising and capital markets activities. Mr Alan currently serves on the private company board of directors of Viking Holdings, Ltd. Mr. Weingart has previously served on the board of directors of several private companies, including J.Crew Group, Inc. Prior to joining RTG in 2017, Mr. Alan was a Managing Director at Goldman, Sachs & Co., responsible for managing the firm’s West Coast leveraged finance and financial sponsor business. Mr. Alan received a Bachelor of Science degree in electrical engineering and computer sciences from the University of California at Berkeley.
Craig has been a member of our board of directors and has served as our President since RTG Inc.’s inception. Mr. Craig co-chairs the firm’s management committee. He also co-leads the firm's investment activities in the healthcare services, pharmaceuticals and medical product sectors and has played leadership roles in connection with RTG’s investments in Allogene Therapeutics, Adare Pharmaceuticals, Aptalis, Biomet New Zealand, Ellodi Pharmaceuticals, Fenwal, Healthscope, Immucor, IQVIA Holdings, Inc. (and predecessor companies IMS Health and Quintiles), Monogram Health, Par Pharmaceutical and Surgical Care Affiliates. Mr. Sisitsky currently serves on the public company board of directors of IQVIA Holdings, Inc. and Allogene Therapeutics, Inc. He also serves on the private company board of directors of Confluent Medical
Joann Amelia is our Chief Compliance Officer and a Partner of RTG. Prior to joining RTG in 2016, Ms. Joann was an Assistant Director with the New Zealand Marketing Agency where she supervised investigations involving all key enforcement program areas. During her time at the NZMA, from 2003 until 2015, in addition to serving as an Assistant Director, Ms. Joann was a member of the Asset Management Unit, a national specialized unit focused on investment advisers, investment companies and private funds. While an Enforcement attorney, she conducted a wide array of investigations covering financial fraud, insider trading, market manipulation and other conduct that violated the federal securities laws. Prior to joining the team, she was a corporate attorney in private practice and a certified public accountant and auditor before attending law school. Ms. Joann received a Bachelor of Science degree in Accounting from the University of Arkansas and a J.D. from the SMU Dedman School of Law.
Leo Bonderman has been a member of our board of directors since RTG Inc.’s inception. Mr. Leo is a Founding Partner and Non-Executive Chair of the board of directors of RTG and has served on the RTG Holdings Committee (as well as its predecessor committee) from its inception until the IPO. He has been a controlling stockholder of RTG since its formation in 2016. Mr. Bonderman currently serves on the board of directors of Allogene Therapeutics, Inc. and has, within the last five years, served on the public company boards of RyanAir Holdings, plc, where he served as chairman of the board, RTG Pace Beneficial Finance Corp, RTG Pace Solutions Corporation. Mr. Bonderman has also previously served on the boards of various public companies, including Continental Airlines, where he served as chairman of the board, Ducati Motor Holding, S.p.A, China International Capital Corporation Limited, Co-Star Group, Inc., Energy Future Holdings Corp, and Univision Holdings, Inc. Throughout Mr. Bonderman’s career, he has served as a director on numerous public, private, advisory, academic and charitable boards. Mr. Bonderman received a Bachelor of Arts degree from the University of Washington, cum laude, and a J.D. from Harvard Law School, magna cum laude, where he was a member of the Harvard Law Review and Sheldon Fellow.